Projects of affiliated persons per year
Abstract
| Original language | English |
|---|---|
| Article number | 7926 |
| Number of pages | 17 |
| Journal | Nature Communications |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 2022 |
Funding
We thank Florian Krammer (Icahn School of Medicine at Mount Sinai, NY, USA) for providing the genetic constructs used for the production of recombinant SARS-CoV-2 Spike protein and RBD. Purified Spike and RBD as well as transfection‐grade mammalian expression plasmids were obtained from the reagent repository of the BOKU COVID‐19 Initiative. The BOKU Spin-off Novasign GmbH created and hosts the BOKU-COVID19 Portal (portal.boku-covid19.at) that enables researchers to access free samples of SARS-CoV-2 antigens described within this work. We acknowledge SuperMUC-NG computing allocation at the Leibniz Supercomputing Centre (M.S. and G.H.). We thank the Max Planck Society (M.S., A.R.M., and G.H.) for support and the Max Planck Computing Data Facility for computational resources. We further acknowledge funding from the German Research Foundation (TA157/12-1 to R.T.), the European Research Council (ERC Advanced Grant No. 789121 to R.T.), the Volkswagen Foundation (96 498 to R.W. and 96 496 to R.T.), and the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no.101005026. The J.U. receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. J.M.P. has received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences, the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101005026, and the Canada 150 Research Chairs Program F18-01336, as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015. This work was further supported by funding from the Austrian National Foundation for Research, Technology, and Development and Research Department of the State of Upper Austria (Y.O.), from the FWF projects W1224 (N.F.K. and L.M.), V584 (Y.O.), P31599 (R.Z.), P30314 (P.H.), I3183 (P.H.), FWFP35166000 (M.K., P.H.), the WWTF grant LS19-029 (P.H., D.C.), the ÖAW fellowship STIP13202002 (L.H.), the European Union’s Horizon research and innovation program (grant no. H2020-MSCA-ITN-2016) under the Marie Skolodowska-Curie grant agreement No. 721874 (P.H. and D.C.), the FWF Schroedinger fellowship J4332-B28 (M.S.). We thank Florian Krammer (Icahn School of Medicine at Mount Sinai, NY, USA) for providing the genetic constructs used for the production of recombinant SARS-CoV-2 Spike protein and RBD. Purified Spike and RBD as well as transfection‐grade mammalian expression plasmids were obtained from the reagent repository of the BOKU COVID‐19 Initiative. The BOKU Spin-off Novasign GmbH created and hosts the BOKU-COVID19 Portal (portal.boku-covid19.at) that enables researchers to access free samples of SARS-CoV-2 antigens described within this work. We acknowledge SuperMUC-NG computing allocation at the Leibniz Supercomputing Centre (M.S. and G.H.). We thank the Max Planck Society (M.S., A.R.M., and G.H.) for support and the Max Planck Computing Data Facility for computational resources. We further acknowledge funding from the German Research Foundation (TA157/12-1 to R.T.), the European Research Council (ERC Advanced Grant No. 789121 to R.T.), the Volkswagen Foundation (96 498 to R.W. and 96 496 to R.T.), and the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no.101005026. The J.U. receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. J.M.P. has received funding from the T. von Zastrow foundation, the FWF Wittgenstein award (Z 271-B19), the Austrian Academy of Sciences, the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101005026, and the Canada 150 Research Chairs Program F18-01336, as well as the Canadian Institutes of Health Research COVID-19 grants F20-02343 and F20-02015. This work was further supported by funding from the Austrian National Foundation for Research, Technology, and Development and Research Department of the State of Upper Austria (Y.O.), from the FWF projects W1224 (N.F.K. and L.M.), V584 (Y.O.), P31599 (R.Z.), P30314 (P.H.), I3183 (P.H.), FWFP35166000 (M.K., P.H.), the WWTF grant LS19-029 (P.H., D.C.), the ÖAW fellowship STIP13202002 (L.H.), the European Union’s Horizon research and innovation program (grant no. H2020-MSCA-ITN-2016) under the Marie Skolodowska-Curie grant agreement No. 721874 (P.H. and D.C.), the FWF Schroedinger fellowship J4332-B28 (M.S.).
Austrian Fields of Science 2012
- 106006 Biophysics
- 106002 Biochemistry
- 106022 Microbiology
Fingerprint
Dive into the research topics of 'Force-tuned avidity of spike variant-ACE2 interactions viewed on the single-molecule level'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Multiscale simulations of cell adhesion receptor clustering
Sikora, M. (Project Lead) & Dellago, C. (Co-Lead)
1/05/19 → 31/07/21
Project: Research funding
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver